VNRXVNRXHealthcare · Medical Devices

VNRX Stock Forecast: VolitionRX Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.16
+1.31% on the day

The median 12-month analyst price target for VolitionRX Ltd. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$5.8M
Ticker Nerd rank
53/ 100
Median analyst target
$20
Analysts covering
5
Revenue$399K−2.0% y/y
Operating income−$4.2M
Net income−$7.3M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.5%
1M
−4.6%
YTD
−96.9%
1Y
−97.5%
From 52W high
−97.7%
From 52W low
+1.3%
$0.16
$7.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores VolitionRX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
84
Growth
84
Issuance
55
Accruals
38
Volatility
29
Quality
24
Momentum
20
Value
19

Revisions (84): Analysts have, on balance, been raising their forecasts.

Value (19): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VNRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VNRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26VNRXHigh $24Median $20Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3
Buy
2
Hold
0
Sell
$2
Low
$20
Median
$24
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Apr 2026D. Boral CapitalDowngradeHold—
2 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
9 Jan 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
3 Dec 2025Maxim GroupDowngradeHold—
26 Nov 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Freedom BrokerMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
29 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
17 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VNRX.

Market Radar

This page is one stock. Monday covers all of them.

VNRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VNRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, VolitionRX Ltd. returned −97.5% against +6.9% for the S&P 500, dividends included.

VNRX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26VNRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VNRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.7×

Cheaper than 53% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−161.9%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • VolitionRX Ltd. has a market value of $5.8M and an enterprise value of $10.2M.

  • Revenue in the twelve months to 30 June 2026: $2.5M. The latest quarter shrank 2.0% year on year.

  • Net income over the same four quarters: −$25.7M, a −1046.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.6M.

  • Shares outstanding: 12.0M.

  • VolitionRX Ltd. employs 54 people — $46K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

VNRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VNRXVolitionRX Ltd.$5.8M53
NMTCNeuroOne Medical Technologies Corp.$5.9M36
ARAYAccuray, Inc.$6.2M46
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
BMRABiomerica, Inc.$5.0M11
WOKWORK Medical Technology Group Ltd.$4.9M16

Take a look at VNRX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own VolitionRX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VNRX

What is the VNRX stock price forecast for 2026-2027?

The median 12-month analyst price target for VolitionRX Ltd. is $20, with estimates ranging from $2.11 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VNRX stock a buy right now?

Of the 5 analysts covering VolitionRX Ltd., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VolitionRX Ltd. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VNRX?

As at 21 Nov 2026, VolitionRX Ltd. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).

Will VNRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $20, and Ticker Nerd's factor model ranks VolitionRX Ltd. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VNRX stock forecast for 2030?

No analyst covering VolitionRX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.11 to $24 over the next 12 months.

How has VNRX stock performed over the past year?

VolitionRX Ltd. returned -97.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VolitionRX Ltd. do?

VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis.

Company

About VolitionRX Ltd.

VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis. The company also offers veterinary applications such as Nu.Q Vet and research tools such as Nu.Q Discover, alongside technologies designed to support earlier disease detection and treatment monitoring. VolitionRx Limited serves healthcare and life sciences markets across the United States, Europe, and Asia from its headquarters in Henderson, Nevada.

CEO Mr. Cameron Reynolds MBA · 54 employees · United States · https://volition.com